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Background  :  Spontaneous  delayed  clearance  of  hepatitis  B  surface  antigen  (HBsAg)  in  patients  with  chronic  HBV 
infection  is  a  rare  event.  The  aim  of  this  study  was  to  investigate  the  incidence  of  delayed  clearance  of  serum  HBsAg 
in  chronic  HBV  infection  and  to  determine  the  characteristics  and  clinical  outcomes  of  HBsAg  delayed  clearance  in 
Korean  patients. 
Methods  :  From  April  1981  to  June  2003,  4,061  patients  who  were  positive  for  HBsAg  were  evaluated 
retrospectively.  The  following  assessments  were  undertaken  in  47  patients  who  had  spontaneous  delayed  clearance: 
liver  biochemistry,  viral  markers,  α-fetoprotein  levels,  and  radiographic  examinations  including  ultrasonography  every 
three  to  six  months  for  6-264  months  (median  87.9  months). 
Results  :  Twenty-four  of  47  patients  were  asymptomatic  carriers.  The  others  included  seven  patients  with  chronic 
hepatitis,  seven  with  liver  cirrhosis  and  nine  with  hepatocellular  carcinoma.  The  estimated  annual  incidence  of  HBsAg 
seroclearance  was  0.4%.  The  time  span  from  positive  HBsAg  to  HBsAg  seroclearance  in  the  AHC,  CH,  LC,  and  HCC 
was  62.9,  141,  63,  and  95.3  months  during  follow  up.  Twenty-four  of  24  AHC  remained  normal,  5  of  7  CH  remained 
as  CH  and  2  patients  remained  normal,  1  of  7  with  LC  developed  HCC  and  6  of  the  LC  remained  as  LC,  and  4  of 
9  HCC  patients  died. 
Conclusion  :  The  clinical  course  following  delayed  clearance  of  HBsAg  had  diverse  outcomes  from  AHC  to  HCC. 
Therefore,  these  patients  require  close  follow  up  for  the  possible  development  of  hepatocellular  carcinoma  following 
HBsAg  clearance.
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INTRODUCTION 
The  Hepatitis  B  virus  (HBV)  is  the  main  cause  of  acute  and 
chronic  liver  disease  worldwide
1, 2).  The  presence  of  hepatitis  B 
surface  antigen  (HBsAg)  in  the  serum  for  more  than  six  months 
defines  the  state  of  chronic  HBV  infection
3, 4).  The  presence  of 
chronic  HBV  infection  is  associated  with  severe  sequelae  such 
as  cirrhosis  and  hepatocellular  carcinoma  (HCC)
5, 6).  Patients 
who  cannot  clear  the  HBV  after  an  acute  infection  generally 
carry  it  indefinitely.  However,  in  a  very  small  proportion  of  these 
patients,  a  spontaneous  delayed  clearance  of  the  HBsAg  may 
occur  during  the  course  of  chronic  infection
7-10).
Generally,  spontaneous  delayed  clearance  of  HBsAg  has 
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Sex  (male/female)
Age
Family  history  of  HBV
Transfusion  history
Operation  history
Alcohol  drinking
Initial  diagnosis
    AHC
    CH
    LC
    HCC
Albumin  (g/dL)
Total  bilirubin  (mg/dL)
ALT  (IU/L)
Alkaline  phosphatase  (U/L)
γ-GTP  (U/L)
HBsAg  positive,  n  (%)
HBeAg  positive,  n  (%)
HBV  DNA  positive,  n  (%)
2639/1422
50±3.6
2558  (63%)
324  (8%)
1137  (28%)
1624  (40%)
366  (9%)
2416  (59.5%)
893  (22%)
386  (9.5%)
3.8±0.6
1.2±0.7
54±46
220±94
55±78
4061  (100%)
1584  (39%)
1949  (48%)
AHC,  asymptomatic  healthy  carrier;  CH,  chronic  hepatitis;  LC, 
liver  cirrhosis;  HCC,  hepatocellular  carcinoma
Table 1. Demographic and Clinical Characteristics of 4,061 HBsAg 
Carriers
HBsAg  infected  state.  Chen
8)  et  al  reported  from  Taiwan  that 
three  (1.6%)  of  189  non-cirrhotic  patients  with  seroclearance 
developed  liver  cirrhosis  and  that  HCC  developed  in  1  (3.4%)  of 
29  patients  with  cirrhosis  and  in  2  (1.1%)  of  189  non-cirrhotic 
patients  during  a  mean  period  of  63  months  after  HBsAg 
seroclearance.  Fattovich
13)  et  al  also  reported  that  patients  with 
compensated  HBV  liver  cirrhosis,  with  HBsAg  delayed 
clearance,  have  a  better  prognosis  than  the  patients  with 
persistent  HBV  infection  do.  However,  Huo
14)  et  al  reported  that 
33%  of  55  patients  with  seroclearance  developed  serious 
sequelae  including  20%  with  HCC  and  9%  with  cirrhosis  during 
a  mean  follow  up  period  of  23  months  after  delayed 
seroclearance. 
Although  many  studies  have  been  reported  on  the  course  of 
spontaneous  delayed  seroclearance  of  HBsAg,  the  prognosis 
following  delayed  seroclearance  has  not  been  well  defined.  This 
retrospective  study  was  designed  to  investigate  the  rate  of 
delayed  clearance  of  serum  HBsAg  in  chronic  HBV  infection 
and  determine  the  clinical  outcomes  of  patients  with  HBsAg 
delayed  clearance  in  Korea.
MATERIALS AND METHODS
Patients
There  were  4,061  patients  newly  diagnosed  with  chronic 
hepatitis  B  from  April  1981  to  June  2003.  They  were  followed 
every  three  to  six  months  at  the  Kangnam  St.  Mary's  Hospital 
in  Seoul,  Korea.  The  enrolled  patients  had  no  co-infections 
such  as  HCV,  HDV  or  HIV.  Patients  identified  with  chronic 
infection  were  HBsAg  positive  for  more  than  six  months  and 
were  regularly  followed  in  the  out  patient  department.  The  follow 
up  period  ranged  from  six  to  264  months  a  mean  period  of  87.9 
months.
Methods
All  patients  were  tested  at  the  first  visit  for  the  following: 
HBsAg  (hepatitis  B  surface  antigen),  antibody  to  HBsAg 
(anti-HBs)  (Abbott  Laboratories,  IL,  USA),  HBeAg  (hepatitis  B  e 
antigen),  antibody  to  HBeAg  (anti-HBe),  antibody  to  hepatitis  B 
core  antigen  (anti-HBc)  (Dainabot  co.,  Tokyo,  Japan),  serum 
aminotransferase  (AST),  alanine  aminotransferase  (ALT), 
albumin,  globulin,  bilirubin,  alkaline  phosphatase,  glutamyl 
transpeptidase,  prothrombin  time,  Alfafetoprotein,  and  HBV  DNA 
(Quantiplex  branched  DNA  assay,  Bayer  Diagnostics,  Berkeley, 
CA,  USA;  sensitivity  >  7x10
5  copies/mL).  Follow  up  included 
testing  for  HBsAg  and  anti-HBs  at  six-month  intervals. 
HBsAg  seroclearance  was  defined  as  the  absence  of  serum 
HBsAg  on  repeated  testing  for  a  period  of  at  least  six  months 
and  during  subsequent  follow-up  until  the  time  of  analysis. 
Those  patients  who  showed  spontaneous  delayed  clearance  of 
serum  HBsAg  were  followed  at  intervals  less  than  every  six 
months.  Delayed  clearance  of  HBsAg  was  defined  by  a 
persistent  absence  of  HBsAg  recorded  in  at  least  two 
consecutive  specimens  from  patients  with  chronic  HBV 
infections.  During  a  mean  period  of  87.9  months,  the  chara-
cteristics  of  patients  who  showed  delayed  HBsAg  clearance 
were  evaluated  using  biochemistry,  viral  markers  and 
radiographic  examinations  including  ultrasonography. 
The  diagnostic  criteria  used  were  as  follows
12).  The 
asymptomatic  healthy  carriers  were  those  with  a  persistent 
normal  serum  alanine  aminotransferase  level  for  at  least  2  years 
on  periodic  biochemical  examinations  every  three  or  six  months. 
The  patients  with  chronic  hepatitis  had  intermittent  or  sustained 
elevations  of  liver  function  tests  and  a  necroinflammatory  score 
above  4  from  liver  biopsy  specimens.  The  patients  with  liver 
cirrhosis  had  laboratory  data  including  low  serum  albumin  and 
platelet  levels  with  features  of  portal  hypertension.  The 
diagnosis  of  HCC  was  made  by  imaging  studies  such  as 
ultrasonography  and/or  computed  tomography  (CT)  and  AFP 
levels  >  400  ng/mL. 
Results
The  patient  characteristics  of  the  4,061  included  in  this  study 
are  presented  in  Table  1.  During  the  period  of  6-264  months  of 
follow  up  (mean  87.9  months)  of  the  enrolled  patients,  47  (1.2%) 
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Patients  (n=) HBsAg  loss Rate
Total  (4061)
AHC  (366)
CH  (2416)
LC  (893)
HCC  (386)
47
24
  7
  7
  9
1.2%
6.6%
0.3%
0.8%
2.3%
AHC,  asymptomatic  healthy  carrier;  CH,  chronic  hepatitis;  LC, 
liver  cirrhosis;  HCC,  hepatocellular  carcinoma
Table  2.  Rate  of  HBsAg  Delayed  Clearance  in  HBV  associated 
chronic  liver  diseases
The  accumulated  annual  incidence  of  HBsAg  seroclearance 
was  0.4%.  HBsAg  seroclearance  was  identified  in  24  (6.6%)  out 
of  366  patients  that  were  asymptomatic  healthy  carriers,  7 
(0.3%)  out  of  2,416  patients  that  developed  chronic  hepatitis,  7 
(0.8%)  out  of  893  patients  that  developed  liver  cirrhosis  and  9 
(2.3%)  out  of  386  patients  who  developed  HCC  (Table  2). 
At  the  time  of  the  diagnosis  of  HBsAg  seroclearance,  there 
were  24  (51%)  asymptomatic  healthy  carriers  and  seven  (14.9%) 
patients  with  chronic  hepatitis.  The  number  of  patients  with 
cirrhosis  and  HCC  were  seven  (14.9%)  and  nine  (19.1%)  from 
the  47  patients,  respectively.  The  mean  age  at  enrollment  was 
50±3.6  and  the  mean  age  at  HBsAg  seroclearance  was  46.2±
15.7.  The  HBeAg  at  enrollment  among  the  47  patients  with 
HBsAg  seroclearance  was  24  negative,  nine  positive  and  14  not 
determined.  The  HBsAb  state  at  HBsAg  seroclearance  was  25 
positive  and  22  negative.  The  time  span  from  positive  HBsAg  to 
HBsAg  seroclearance  in  the  AHC,  CH,  LC  and  HCC  was  62.9, 
141,  63,  and  95.3  months  during  follow  up,  respectively.  The 
diagnosis  at  the  last  visit  of  the  enrolled  patients  was  as  follows: 
24  of  24  AHC  remained  normal,  5  of  7  CH  remained  with  CH 
and  2  patients  remained  normal;  1  of  7  LC  patients  developed 
HCC,  6  of  the  LC  patients  remained  LC,  and  4  of  9  HCC 
patients  died. 
DISCUSSION
Patients  with  chronic  HBV  infection  usually  develop  severe 
sequelae  including  cirrhosis  and  hepatocellular  carcinoma.  In  a 
very  small  proportion  of  these  patients,  spontaneous  delayed 
clearance  of  HBsAg  may  occur  during  the  course  of  chronic 
infection.  The  results  of  this  study  showed  that  delayed  serum 
HBsAg  clearance  was  a  very  rare  event.  The  incidence  of 
spontaneous  delayed  clearance  from  serum  of  HBsAg  was 
1.2%  (47  out  of  4,061  patients)  in  our  study.  The  accumulated 
annual  incidence  was  0.4%.  Previous  reports  of  HBsAg 
seroclearance  suggested  a  0.1%  to  0.8%  annual  incidence
1, 10). 
In  1991,  Liaw
11)  et  al  reported  that  1.9%  of  biopsy-proven 
chronic  hepatitis  patients,  and  2.2%  of  asymptomatic  chronic 
carriers,  cleared  HBsAg  from  their  serum  during  a  mean  follow 
up  period  of  4.0±2.3  years.  In  a  Japanese  study  on 
spontaneous  clearance  of  HBsAg  in  chronic  carriers,  29%  of 
chronic  carriers,  with  a  yearly  incidence  of  2.5%,  had  clearance 
of  the  serum  HBsAg
7).  In  a  Turkish  study,  during  a  mean  follow 
up  period  of  36.8  months,  9.7%  of  patients  cleared  their  HBsAg 
spontaneously
15).  In  a  European  study,  a  10%  rate  of  HBsAg 
seroclearances  in  chronic  carriers  with  HDV  antibodies  was 
reported
13).
The  prognosis  after  spontaneous  delayed  HBsAg 
seroclearance  was  generally  good.  In  our  study,  asymptomatic 
healthy  carriers  were  identified  in  24  out  of  47  patients  with 
HBsAg  seroconversion.  By  contrast,  serious  life  threatening 
sequelae  such  as  cirrhosis  (7  of  47  patients,  14.9%)  and  HCC 
(9  of  47  patients,  19.1%)  developed  in  some  patients  followed 
during  this  investigation.  These  findings  support  several  prior 
short-term  and  long-term  studies
7, 8, 11, 13, 14).  Chen
8)  et  al 
reported  that  the  patients  who  had  concurrent  HCV  and/or  HDV 
infection,  before  spontaneous  HBsAg  seroclearance,  had  a 
significantly  higher  incidence  of  complications  with  a  less 
favorable  prognosis.  However,  Huo
14)  et  al  reported  that 
seroclearance  of  HBsAg,  in  chronic  carriers,  does  not  imply  a 
good  prognosis;  they  found  a  29.8%  overall  cumulative 
probability  of  complications  in  such  patients.  However,  other 
investigators  have  reported  lack  of  correlation  with 
superinfections  such  as  HCV  and/or  HDV
16).  None  of  our 
enrolled  patients  had  concurrent  co-infections.  Our  findings  of  a 
favorable  prognosis  in  patients  with  AHC  and  CH,  with  HBsAg 
seroclearance,  may  be  due  to  this  difference  from  the  patients 
reported  by  Huo
14)  and/or  Chen
8)  et  al.  However,  the  prognosis 
of  LC  and/or  HCC  patients  after  seroclearance  was  less 
favorable;  1  of  the  LC  patients  progressed  to  HCC. 
The  mechanisms  underlying  delayed  serum  HBsAg  clearance 
remain  unknown.  Sheen
17)  et  al  and  Liaw
18)  et  al  reported  that 
superinfection  with  HCV  and/or  HDV  had  a  role  in  the 
termination  of  the  chronic  HBsAg  carrier  or  chronic  hepatitis 
state.  Moreover,  Yeh
19)  et  al  reported  that  seroclearance  of 
HBsAg  could  be  explained  by  the  presence  of  defective  pre-S/S 
genes  in  some  patients,  whereas  superinfection  with  other 
viruses  played  a  more  important  role.  Cirrhosis  and  HCC  also 
develop  in  cases  with  spontaneous  HBsAg  seroclearance. 
Immune  clearance  or  viral  integration  into  the  liver  tissue  may 
weaken  viral  replication,  and  may  play  a  role  in  HBsAg 
seroclearance
14, 20-22).  Therefore,  superinfection,  cirrhosis  and/or 
immune  factors  are  all  likely  to  be  involved  in  the  underlying 
clearance  mechanisms.  The  annual  incidence  of  HBsAg 
seroclearance  in  Western  countries  has  been  reported  to  be  1% 
to  2%
23, 24),  in  Taiwan  0.1%/yr
10)  and  0.4%/yr  in  our  study  on 
Korean  patients.  These  results  could  be  explained  by  the 
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in  hyperendemic  areas;  however,  further  study  is  needed  to 
confirm  the  causes. 
The  limitations  of  this  study  are  as  follows;  first,  an  accurate 
determination  of  the  initial  infection  was  difficult.  Second,  the 
present  study  did  not  show  the  effect  of  HBV  DNA  levels  on 
HBsAg  seroclearance.  Third,  detailed  comparisons  were  not 
possible  because  the  relevant  data  such  as  the  effect  of 
treatment  with  interferon  or  other  antiviral  agents  was  not 
available. 
In  conclusion,  the  incidence  of  delayed  HBsAg  clearance 
during  chronic  HBV  infection  is  low.  The  prognosis  of  patients 
with  delayed  serum  HBsAg  clearance  is  good  except  for  those 
patients  who  develop  cirrhosis  or  HCC.  Long-term  follow  up  of 
HBsAg  seroclearance  may  be  an  important  approach  to 
elucidating  the  natural  history  of  HBsAg  clearance  and 
eradication  of  the  hepatitis  virus  itself.  Furthermore,  patients  with 
liver  cirrhosis  require  meticulous  followed  up  for  serious  life 
threatening  complications. 
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